Peterson Caryn 4

What Happened

• Caryn Peterson, EVP of Regulatory Affairs at Gossamer Bio, did not buy or sell company stock; instead, on March 19, 2026 the company cancelled a set of existing stock options and granted replacement (repriced) options. The filing records dispositions to the issuer (D) totaling 1,992,203 option units and matching grants/awards (A) totaling 1,992,203 option units.
• The repriced options set the per-share exercise price at $0.45 (effective March 19, 2026). The Form 4 reports derivative transactions (options) and does not show cash proceeds or a share-for-share sale price (price and total value shown as N/A).

Key Details

• Transaction date: March 19, 2026; Form 4 filed March 20, 2026 (timely).
• Transaction codes: D = disposition to issuer (old options cancelled), A = grant/award (new repriced options).
• Total options affected: 1,992,203 canceled and 1,992,203 repriced/granted.
• New exercise price: $0.45 per share (per footnote F1).
• Vesting: Unchanged and governed by the original award agreements; new options vest per the previously reported schedules and require continued service (footnote F2).
• Shares owned after transaction: Not specified in this filing.
• Filing timeliness: No late filing indicated.

Context

• This is a derivative repricing (administrative amendment of option strike price), not an open-market purchase or sale of shares. No shares were reported as exercised or sold to the market in this filing. Repricings are routine corporate actions to modify option economics; they do not by themselves indicate insider buying or selling of stock.